Preconception care: screening and management of chronic disease and promoting psychological health

Zohra S Lassi, Ayesha M Imam, Sohni V Dean, Zulfiqar A Bhutta*

Abstract

Introduction: A large proportion of women around the world suffer from chronic diseases including mental health diseases. In the United States alone, over 12% of women of reproductive age suffer from a chronic medical condition, especially diabetes and hypertension. Chronic diseases significantly increase the odds for poor maternal and newborn outcomes in pregnant women.

Methods: A systematic review and meta-analysis of the evidence was conducted to ascertain the possible impact of preconception care for preventing and managing chronic diseases and promoting psychological health on maternal, newborn and child health outcomes. A comprehensive strategy was used to search electronic reference libraries, and both observational and clinical controlled trials were included. Cross-referencing and a separate search strategy for each preconception risk and intervention ensured wider study capture.

Results: Maternal prepregnancy diabetic care is a significant intervention that reduces the occurrence of congenital malformations by 70% (95% Confidence Interval (CI): 59-78%) and perinatal mortality by 69% (95% CI: 47-81%). Furthermore, preconception management of epilepsy and phenylketonuria are essential and can optimize maternal, fetal and neonatal outcomes if given before conception. Ideally changes in antiepileptic drug therapy should be made at least 6 months before planned conception. Interventions specifically targeting women of reproductive age suffering from a psychiatric condition show that group-counseling and interventions leading to empowerment of women have reported non-significant reduction in depression (economic skill building: Mean Difference (MD) -7.53; 95% CI: -17.24, 2.18; counseling: MD-2.92; 95% CI: -13.17, 7.33).

Conclusion: While prevention and management of the chronic diseases like diabetes and hypertension, through counseling, and other dietary and pharmacological intervention, is important, delivering solutions to prevent and respond to women’s psychological health problems are urgently needed to combat this leading cause of morbidity.

Introduction

Preconception care for women with underlying chronic diseases is very crucial. Worldwide, 60 million women of reproductive age have type-2 diabetes [1]. While diabetes has known macro- and micro-vascular complications, this increasing prevalence in women of reproductive age makes it a serious health concern for those to-be mothers and their newborns. Diabetes during pregnancy is associated with increased risk for miscarriages, stillbirth, macrosomia and obstetric complications, intrauterine developmental and growth abnormalities, birth and neonatal complications [2,3]. Strict control of blood glucose during pregnancy is necessary, however counseling, diet modification and tight glycemic control in the preconception period offer a greater benefit to maternal and newborn outcomes.

Thyroid disease is another prominent chronic illness in women of child-bearing age, second only to diabetes. Thyroid hormone imbalances during pregnancy, particularly during the first trimester, are known to cause intellectual impairment of the offspring as well as pregnancy complications including hypertension and preeclampsia, placental
abruption, anemia, postpartum hemorrhage, preterm birth, low birth-weight and fetal death [4].

Phenylketonuria is an important metabolic disorder that has been associated with neurological sequelae and congenital heart defects in neonates if levels of phenylalanine are not controlled during pregnancy [5]. Therefore, the most favorable period to achieve control is before conception.

Other than the physical health of women of childbearing age, their mental health is equally important in ensuring healthy outcomes for both mother and child. Mood and anxiety disorders are highly prevalent among women of reproductive age and there is evidence that new-onset illness or a relapse is highly prevalent during pregnancy [6]. Psychiatric disorders during pregnancy have been associated with poor obstetric outcomes, higher risk of postpartum psychiatric illness, increased rates of substance abuse, and lower participation in prenatal care leading to adverse infant outcomes [7,8]. Intimate partner violence (IPV) has serious consequences for women’s psychological and physical health. Victims of IPV are at high risk of unplanned pregnancy due to sexual coercion.

Prior to taking on the challenge of supporting another life, women should be in their optimal physical and psychological health. This paper highlights the maternal and fetal risks from uncontrolled chronic diseases and potential interventions that have been effective in alleviating these risks. This paper has also assessed the risks associated with psychological health and IPV in particular and the interventions that have met with some success in dealing with these.

Methods
This paper systematically reviewed all the literature published up to 2011 to identify studies describing the effectiveness of preconception interventions (any intervention provided to women and couples of childbearing age, regardless of pregnancy status or desire, before pregnancy or between two pregnancies, to improve health outcomes for women, newborns and children period before pregnancy and between pregnancies) and risks for preventing and managing chronic diseases and promoting psychological health for improved maternal, newborn and child health (MNCH) outcomes. Electronic databases such as PubMed, Cochrane Libraries, Embase, and WHO Regional Databases were searched to identify the experimental and observational studies on the subject. Papers were also identified by hand searching references from included studies. No language or date restrictions were applied in the search. The findings were presented at international meeting [9,10] and shared with professionals in the relevant fields of maternal and child health, following which results were updated based on current searches (through end of 2012) and expert opinion. Studies were included if they reported the effectiveness of interventions for preventing and managing chronic diseases and promoting psychological health on MNCH outcomes. The methodology is described in detail elsewhere [11].

Two authors assessed the eligibility of studies and extracted data and judged the quality on standardized sheets. The quality of experimental studies were assessed using Cochrane criteria [12], whereas STROBE guidelines were used to assess the quality of observational studies [13]. We conducted meta-analyses for individual studies and pooled statistics was reported as the odds ratio (OR) and relative risk (RR) between the experimental and control groups with 95% confidence intervals (CI). Mantel–Haenszel pooled RR and corresponding 95% CI were reported or the Der Simonian–Laird pooled RR and corresponding 95% CI where there was an unexplained heterogeneity. All analyses were conducted using the software Review Manager 5.1 [14]. Heterogeneity was quantified by Chi² and I², in situations of high heterogeneity, causes were explored through sub-group analysis and random effect models were used.

Results
The review identified 2065 papers from search in all databases. After the initial title and abstract screening, 187 full texts were reviewed to identify papers which met the inclusion criteria and had the outcomes of our interest. One hundred and sixty one studies were finally selected for abstraction and analysis (Figure 1). Information related to each included study can be found on the following link:

https://globalmotherchildresearch.tghn.org/site_media/media/articles/Preconception_Report.pdf

Diabetes
Diabetes continues to be an ever-increasing global problem. The prevalence of Type 2 (characterized by hyperglycemia in the context of insulin resistance and relative lack of insulin) diabetes continues to increase worldwide [15,16], especially in the low and middle income countries (LMICs) [17,18]. This in turn means more women of reproductive age in LMICs have diabetes, hence a greater number of pregnancies are complicated by the condition [19,20] putting both the mother and the fetus at an increased risk of morbidity and mortality [21]. Diabetes in pregnancy is associated with elevated rates of miscarriage [22], pre-eclampsia [23,24], preterm labor and caesarean sections [25,26] and higher rates of fetal malformation [2,3,25,27] neural tube defect, urinary tract disorder, macrosomia [28,29], birth injury [26,27,30], and perinatal mortality [31,32].

Preconception diabetic care is a multidisciplinary approach with the goal of care being to obtain the lowest
possible hemoglobin A1C without significant episodes of hypoglycemia. The content for preconception care broadly includes educating the patient with regards to the disease and its interplay with pregnancy; educating the patient about self-management skills; physician-directed assessment and care of the disease and complications; counseling about diet, exercise and reproductive advice.

The review identified 22 observational studies [32-53] and one trial [54] that looked at various outcomes related to pre-gestational diabetes. Meta-analysis of 21 studies showed that preconception care was able to reduce the occurrence of congenital malformations (RR 0.30; 95% CI: 0.22-0.41) (Figure 2). Pooled data for the effect of preconception care on the risk of perinatal mortality was also significant (RR 0.31; 95% CI: 0.19-0.53) with counseling plus strict glycemic control leading to a 71% reduction in the events in this group compared to the standard antenatal care group (Figure 3).

When looking at pregnancy complications, the meta-analysis supported the effectiveness of preconception care in non-significantly reducing the rate of preterm delivery (RR 0.83; 95% CI: 0.62-1.12) and of caesarean sections (RR 0.97; 95% CI: 0.77-1.23) [39,41,48,50,53]. Results for other fetal/neonatal outcomes [53] and macrosomia [48,50,51] were also non-significant. The data revealed that preconception care was valuable in significantly dropping the level of HbA1C during the first trimester of pregnancy (MD -1.71; 95% CI: -2.72,-0.71) [32-34,38,40,45-47,55,56]. As hyperglycemia during the period of organogenesis leads to an increased risk of congenital malformations, this achievement of better glycemic control in the 1st trimester may explain the concurrent reduction of anomalies as well as subsequent perinatal death. A single study by Heller et al. [54] showed a weak non-significant effect of preconception insulin in reducing the 1st trimester HbA1C as compared to commencement of insulin in early pregnancy (MD -0.10; 95% CI: -0.27, 0.06).

**Epilepsy management**

Epilepsy is a condition in which a disruption of the normal electrochemical activity of the brain results in seizures. Women with epilepsy during their child-bearing years not only face the possible risk for adverse pregnancy outcome as a result of the teratogenic effects of antiepileptic drugs upon [57,58] but also the potential effect of maternal seizures on the developing fetus [59-61]. Most women with epilepsy have no change in seizure frequency during pregnancy but about 15-33% report increased episodes of seizures during pregnancy [62]. This may be due to a change in the pharmacokinetics of the anti-epileptic drugs [63] or due to the hormonal changes occurring in pregnancy [64]. Unplanned pregnancies rates in women are high but these may be
even higher in women with epilepsy because antiepileptic drugs interfere with hormonal contraception [65]. Different drugs lead to different types and different rates of anomalies, with the highest rates being associated with valproate [66,67].

Preconception care of women with epilepsy includes a careful revision of each case to ascertain the diagnosis, the need for continued anti-epileptic drug therapy, selection of suitable drugs with optimization of the dosage, and prescription of folic acid to prevent neural tube defects.

We found one study [68] that assessed the effectiveness of preconception counseling in women with epilepsy reported that none of the 85 women who were counseled before pregnancy had an abnormal fetus in the subsequent pregnancy as compared to almost 19% of the women who did not receive any preconception counseling (as they were already pregnant) who had an abnormal fetus (with 3 pregnancy terminations). One patient in the counseled group had an early miscarriage, followed by a normal subsequent pregnancy, and 1 had a preterm birth compared to 3 preterm births in the control group. They also showed that post-counseling 71% of women with epilepsy used a single drug and none used >2 drugs as compared to 32% and 20% respectively in the control
group. Most of the counseled women used carbameza- 
pine/lamotrigine compared to the control women with 
epilepsy, 41% of whom used valproate.

Management of phenylketonuria
Phenylketonuria (PKU) is caused by the deficiency of 
phenylalanine hydroxylase which is required to essential 
amino acids, phenylalanine (phe), to tyrosine [69]. These 
women are advised to consume phe free food to live a 
normal life. These women during pregnancy require 
appropriate management as poor disease control is asso- 
ciated with a multitude of fetal consequences like facial 
dysmorphism, microcephaly, developmental delay, learn- 
ing difficulties and congenital heart disease [69,70].

This review accumulated evidence from current litera- 
ture on the effect of maternal PKU on the pregnancy 
outcome, specifically of preconception levels of phenyla- 
lanine. The review also looked for any preconception 
intervention which worked in lowering the maternal, 
newborn and child health (MNCH) risks associated with 
poorly controlled phenylalanine levels. Preconception 
care of women with PKU consists of counseling regard- 
ing the fetal risks (facial malformations, growth deficits, 
microcephaly) associated with the disease, commence- 
ment of a phenylalanine restricted diet, attaining safe 
phenylalanine levels (100–360 μmol/L [72] or <6mg/dL [73,74] atleast 3 months before conception; 
and maintaining them throughout gestation). When 
counseling patients great importance has to be put on 
the need for effective contraception till such safe levels 
are reached.

The review identified seven studies [70,75-80]. Rouse 
et al. [70] in a cohort of women with blood phenylala- 
nine levels >240μmol/L found that mean phenylalanine 
levels at 4 to 8 weeks gestation predicted congenital 
heart defect (P<0.0001). They also found that each 
abnormality increased in frequency as phenylalanine 
control was delayed. The percentage of offspring with 
>3 dysmorphic features (49% overall) was related to 
time of inadequate maternal Phenylalanine control.
Addressing thyroid disorders preconceptionally

Women of child bearing age may suffer from hypo- or hyper-function of the thyroid gland, more often than not due to an autoimmune process. Hypothyroidism during pregnancy is known to lead to adverse maternal (gestational hypertension and pre-eclampsia [81], postpartum hemorrhage, abortion [4] and preterm delivery [82,83]), fetal (congenital anomalies, growth retardation [84], perinatal death) [82] and neonatal consequences (cognitive disorders) [85]. Literature on the association between thyroid disease during pregnancy and preterm delivery is most abundant, with most attributed to autoimmune thyroid disease [86-89]. Among the most frequent complications are the hypertensive disorders of pregnancy, also reported are spontaneous abortion and preterm delivery [90].

While literature on the effect of thyroid status on maternal, fetal and neonatal effects is abundant, much work still needs to be done with regards to the effect of preconceptional thyroid status on these outcomes. Many recommend attainment of a TSH <2.5mU/L before the start of pregnancy. Since purely preconception literature was unavailable, the review looked at the effect of preconceptional interventions addressing adverse pregnancy related outcomes and even those studying the effect of the disease and treatment on MNCH outcomes. Content of preconception care for women with thyroid disorders consists of a thorough assessment of the disease status, advice on the achievement of a euthyroid status well before conception, counseling about the pregnancy-related risks associated with thyroid dysfunction. Medications need to be adjusted in order to have optimal thyroid function and the importance of useful contraception should be stressed upon till such a time.

Thyroid status at the time of conception plays an important role. According to the study by Abalovich et al. [85] none of the women who were euthyroid at the time of conception experienced preterm deliveries. Mestman et al. [91,92] underscores the importance of pre-pregnancy counseling for hyperthyroid women and the use of contraception until achievement of a euthyroid status before conceiving. Earl et al. [93] found no interventions for the prevention and treatment of hyperthyroidism during pregnancy. Their result for usage of antithyroid drugs (ATD) was inconclusive due to the small potential risk of adverse fetal effects of methimazole and maternal effects of propylthiouracil. Another study reports that both ATDs are equally effective and safe in the treatment of hyperthyroidism in pregnancy [94]. Periconception use of ATD was however; shown to significantly increase the rates of selected birth defects (Figure 4) [95].

Browne et al. [95] also reported an association of periconception thyroxine and selected birth defects. Rotondi et al. [96] conducted a trial on the preconception adjustment of levothyroxine and found that it may lead to adequate thyroid function in the 1st trimester; however they did not look at any MNCH outcome. Results suggest that in hypothyroid women anticipating pregnancy (with serum TSH in the lower quartile of normal range), the pre-conception adjustment of L-T4 doses may result in adequate maternal thyroid function up to the first post-conception evaluation [96].

Vaquero et al. [97] reported that in thyroid supplementation group (66mg of thyroid extract, started before conception and continued until the 20th week) among patients with thyroid antibodies, 13 out of 16 pregnancies (81.2%) ended in live birth. Only one pregnancy loss occurred among patients with a mild underlying thyroid pathology treated with thyroid replacement therapy.

Systemic lupus erythematoses and other connective tissue diseases

Systemic lupus erythematosus (SLE) predominantly affects women in the childbearing age group, and thus the effect of pregnancy on the disease and vice versa is an important consideration in the management of these patients. Despite all the advances in understanding the disease pathology and management options pregnancy in lupus is still considered to be a high-risk pregnancy [98]. There is a higher rate of fetal loss, pre-term delivery and IUGR in lupus pregnancies [98-100]. Pre-existing hypertension or renal dysfunction further increases the risk of pre-eclampsia and pregnancy-induced hypertension (PIH) [100-102]. Several studies have found the frequency of
fetal loss to vary between 11-24% [99,103-106]. While some studies advocate that active disease increases the risk of fetal loss [104,107,108], other studies show no statistically significant difference between pregnancies in women with active lupus and those in women with inactive lupus [109,110]. Active disease at conception is a known predictor of poor outcome [102,109,111]. A flare during the year prior to conception pointed to increased risks of a flare again during pregnancy [112,113].

SLE is a prime example of an autoimmune disorder. The review used this disease to study the possible effects of autoimmunity on MNCH outcomes. The review also looked at the effects of treatment modalities for SLE and how, if any available intervention (like counseling, behavioral programs) targeting such women improved the pregnancy outcomes.

The review found a number of observational studies looking at the effect of active disease in the preconception period on pregnancy related outcomes [77,102,108,109,114-128]. The analysis showed that preconception active SLE was associated with multiple maternal and fetal/neonatal outcomes. An active disease increased the risks of gestational flares by 77% (P 0.04) (Figure 5) [117,123,125-127]. There was an over three-fold increase in the risk of developing PIH if the disease was active (specifically with nephritis) before pregnancy (p=0.002); no association was found with risk of preeclampsia. There was also a significant rise in the preterm deliveries if the disease was not in remission before conception (RR 1.71; 95% CI: 1.18-2.48); this risk was further increased by 13% if the woman suffered from active nephritis pre-pregnancy.

Coming to adverse SLE related fetal/neonatal outcomes, it was seen that a positive disease activity in the preconception period significantly increased perinatal mortality (RR 2.42; 95% CI: 1.06, 5.51) (Figure 6) [102,108,117,123,125,127,128]. No association was seen with either spontaneous abortions (RR 3.26; 95% CI: 0.58-18.14) [108,123] or restricted fetal growth (RR 0.61; 95% CI: 0.16-2.28) [127]. Similar findings were reported by Smyth et al. [129].

Other chronic conditions

Chronic hypertension and heart disease – pregnancies complicated by chronic hypertension are associated with increased risk of hypertensive disorders of pregnancy and other organ dysfunctions as well as increased fetal risks of preterm birth, intrauterine growth retardation, fetal loss, hypospadias and abruption placenta [130].

Romunstad et al. [131,132] found a significant association between prepregnancy systolic as well as diastolic blood pressure and low birth weight (LBW). Magnussen et al. [133] found systolic blood pressures of greater than 130mmHg to increase the risk of pre-eclampsia by more than 7 times. Because there is an increasing burden of unplanned pregnancies, fetal exposure to antihypertensive medications might occur before a woman knows she is
pregnant. Caton et al. [130] studied the effect of periconception use of anti-hypertensives and found a positive association with the occurrence of hypospadias (OR 1.90; 95% CI: 1.00-3.61) [130], with a non-significant increase with exposures only to antiadrenergic agents at any time between 1 month preconception and the fourth month of pregnancy. Hameed et al. [134] found an increased risk of spontaneous abortion, cardiac anomaly (4-14%) in the presence of maternal congenital heart disease (CHD).

**Asthma** - Research demonstrates that women with severe asthma prior to pregnancy is more likely to worsen during pregnancy. This reinforces the importance of adequate asthma control prior to conception [135]. Asthma that is not adequately controlled during pregnancy can result in serious maternal complications (preeclampsia, hypertension, and hyperemesis gravidarum) [136] as well as increased fetal complications (stillbirth and infant death, neonatal hypoxia, intrauterine growth retardation, premature birth, and LBW) [137]. It is observed that the dangers of uncontrolled asthma are greater than the risks of indispensable asthma medications. Whereas oral corticosteroid use in the first trimester has been associated with reduced birth weight, an increased risk of preeclampsia, and an increased risk of oral clefts [138,139]. Analysis showed that periconception use of asthma medications was significantly linked to a greater risk of gastroschisis (OR 2.12; 95% CI: 1.39-3.24) [140] especially the use of bronchodilators which significantly doubles the risk.

**Chronic renal disease** - Adverse pregnancy outcomes associated with maternal renal disease include preeclampsia, anaemia, chronic hypertension, caesarean delivery, preterm delivery, fetal growth restriction, and increased fetal loss and stillbirth [141,142]. Renal hypertension is associated with a 10-fold increase in fetal loss compared to women with spontaneously or therapeutically normal blood pressures [143].

**Headache** – frequent pre-pregnancy headaches were found to be statistically significantly associated with poor mental health in the first 3 months of gestation as well as with antepartum depression [144].

**Multiple sclerosis** - Vukusic et al. 2004 [145] reported that women with greater disease activity in the year before pregnancy have a higher risk of relapse in the postpartum 3 months (OR 1.3, p 0.04).
Medication use

Medication usage among pregnant women and women of reproductive age is common. It has been estimated that more than 80% of pregnant women take over-the-counter or prescription drugs during pregnancy [146]. National surveys among women of reproductive age document that chronic conditions often requires the ongoing administration of medications for maintenance are not uncommon among women of reproductive age [147]. As maternal age and body mass index increases, it is likely that an even greater proportion of women who are planning a pregnancy or who could become pregnant will have chronic diseases that necessitate prescription medications. Generally, medication carries a risk of unwanted side-effects which may have profound impacts during pregnancy.

The aim was to look for studies assessing interventions dealing with the repercussions of various medications being frequently used by women. Regular medications being used by women suffering from chronic diseases are covered in the sections of their respective disorders. Studies particularly addressing the deleterious effects of medications, on the health of both the mother and the fetus, when taken in the period before conception were assessed. The review found studies assessing the effect of use of weight-loss drugs, oral contraceptives and vasoactive agents.

Weight loss drugs - Analysis of the effect of periconception use of weight-loss drugs showed a significant association with overall higher rates of congenital anomalies (OR 1.59; 95% CI: 1.33-1.89) [148]. This association was stronger for congenital heart defects with an 88% increase in incidence of Dextro-Transposition of the great arteries and a 58% increase in the incidence of Left Ventricular Outflow Tract Obstruction (LVOTO) (OR 1.88; 95% CI: 1.33-2.65); (OR 1.58; 95% CI: 1.22-2.04) respectively. Bitsko et al. [148] reported the association with ‘Aortic Stenosis’ to be highest among the LVOTO defects (OR 1.2; 95% CI: 0.5-3.1).

Oral contraceptive pills (OCPs) – several studies identified that reported OCPs and maternal and fetal outcomes [133,149-151] No significant association was found between pre/peri-conception use of oral contraceptives and gestational hypertension [150], pre-eclampsia [133,150], preterm delivery, spontaneous abortion (Figure 7), however periconception use of oral contraceptive pills (OCP) lead to an almost three-fold increase in the risk of Down’s in infants (RR 2.71; 95% CI: 1.48-4.95) [151].

Vasoactive substances - Werler et al. [152] reported aspirin use in the periconception period led to a significantly greater risk of amniotic bands (OR 2.5; 95% CI: 1.4-4.6). Vasoconstrictor and decongestant use led to a higher incidence of transverse limb defects (OR 1.4; 95% CI: 1.1-2.0) and (OR 1.7; 95% CI: 1.2-2.3) respectively.

Anti-hypertensive medications - Caton et al. 2008 [130] observed slight to moderate elevations in the risk of severe hypospasias for maternal untreated hypertension (OR 2.1; 95% CI: 1.6-2.9) and antihypertensive medication use during 1 month preconception through pregnancy month 4 (OR 1.4; 95% CI: 0.7-2.9).

Bronchodilators – Lin et al. 2008 [140] reported significant association of maternal bronchodilator use with gastroschisis (OR 2.06, 95% CI: 1.19, 3.59).

Thyroxin – Few studies [95,96,153] reported nonsignificant association with birth defects (OR 1.7; 95% CI: 1.0-2.7).

Any illness/common cold - A study by Krapels et al. 2006 [154] displayed an association of any maternal illness and common cold in periconception period (3 months before conception to 3 months after) with orofacial defects. Cleft lip with or without cleft palate increases by 1.7 times (95% CI: 1.2-2.5) and cleft palate only by 1.5 times (95% CI: 0.8-2.6).

Mental health

With the current prevalence of psychiatric illnesses, there is a significant risk of women’s antenatal and post-partum periods being made difficult with the onset or recurrence of a psychiatric illness. Evidence suggests that depression and anxiety during pregnancy and postpartum severely impact family life, the mother-infant relationship, and the future mental health of the child [6-8,155]. A large meta-analysis stated that up to 18% of women experience depressed mood during pregnancy [156]. A Brazilian study noted that common mental disorders, in general, were autonomously related with LBW and post-traumatic disorder (PTD) in pregnant teenagers [157]. Maternal antenatal depression generally has been highly correlated with PTD [158-160]. Similarly, depression also appears to be a significant risk factor for LBW [159,161,162]. Depression also has noteworthy associations with miscarriage, antepartum hemorrhage, greater uterine artery resistance and a higher risk of operative deliveries [161]. Additional risks are associated with the medications being used to treat depression. Selective serotonin reuptake inhibitor (SSRIs) has been linked with earlier gestational age and lower birth rate [163,164]. Other studies also suggest first trimester exposure to SSRIs increasing the risks restricted fetal growth [165,166].

Bipolar disorder is a severe recurrent illness that is associated with high rates of morbidity and mortality in the absence of adequate treatment. Manic episodes may be associated with increased risky behaviors such as sexual activity or substance use, which could affect health during pregnancy as well as lead to a significant risk of unintended pregnancies [167]. Patients with bipolar disorder
have a very high risk of comorbid alcohol or substance abuse disorders – reaching up to 60% in some studies - which could have direct adverse impacts on fetal outcomes [168,169].

The review assessed the effect pre-existent psychiatric conditions in women in the preconception period on maternal and fetal morbidity and mortality. Included were more prevalent conditions like mood disorders as well as conditions like schizophrenia. The review looked primarily at the risks and benefits, to the mother as well as her unborn child, of continuing or changing or even discontinuing the psychotropic regimens for the above mentioned disorders.

While the effect of psychiatric conditions and their relative treatment during pregnancy has been widely studied [170-189], there is a serious lack of evidence of how pre-pregnancy disease and psychotropic drugs may affect pregnancy. The review found that pre-pregnancy depression is significantly related to preterm births (OR 1.04; 95% CI: 1.02-1.07) [171] and adolescent depression per say was significantly associated with an increased risk of miscarriages (OR 2.25; 95% CI: 1.12-4.50) [172]. When assessing for maternal morbidity, adolescent depression was positively associated with suffering from intimate partner violence (IPV) (OR 3.47; 95% CI: 1.11-10.84) but not with sexually transmitted infections (STIs) (OR 1.50; 95% CI: 0.83-2.72) [172]. Silverman et al. [173] concluded that a pre-existing psychiatric condition was one of the best predictors of development of post-partum depression. Literature also showed that a pre-pregnancy psychotic or bipolar illness substantially increased the risk of a postpartum psychotic or bipolar event [174]. The search for the effect of maternal bereavement on neonatal/infant health revealed that loss of a close relative in the 7-12 months before conception did not increase the risks of autism, epilepsy or febrile seizures in the infant. However, loss of a child or spouse in the 6 months preceding conception was positively associated with attention deficit hyperactivity disorder (ADHD) in the male child, childhood obesity and congenital malformation.

Interventions specifically targeting women of reproductive age suffering from a psychiatric condition show that group-counseling [175] and interventions leading to empowerment of women have reported lowering of depression in these women but the results so far have not

---

**Figure 7** Pregnancy outcomes of Pre/Periconception use of oral contraceptives evidence from observational study.

| Study or Subgroup                  | log(Odds Ratio) | SE  | Weight | Odds Ratio IV, Random, 95% CI | Odds Ratio IV, Random, 95% CI |
|-----------------------------------|-----------------|-----|--------|-------------------------------|-------------------------------|
| 21.5.1 Gestational Hypertension   | -0.357          | 0.286| 25.0%  | 0.70 [0.40, 1.23]             |                               |
| Subtotal (95% CI)                 |                 |     | 25.0%  | 0.70 [0.40, 1.23]             |                               |
| Heterogeneity: Not applicable     |                 |     |        |                               |                               |
| Test for overall effect: Z = 1.25 (P = 0.21) |                 |     |        |                               |                               |
| 21.5.2 Pre-eclampsia              | -0.511          | 0.354| 18.9%  | 0.60 [0.30, 1.20]             |                               |
| Magnussen 2007 (2)                |                 |     |        |                               |                               |
| Thandani 1999                   | 0.262           | 0.248| 29.4%  | 1.30 [0.80, 2.11]             |                               |
| Subtotal (95% CI)                |                 |     |        | 0.92 [0.43, 1.95]             |                               |
| Heterogeneity: Tau² = 0.21; Chi² = 3.20, df = 1 (P = 0.07); I² = 69% | | | | | |
| Test for overall effect: Z = 0.22 (P = 0.83) | | | | | |
| 21.5.3 Spontaneous abortion       | -0.598          | 0.382| 17.0%  | 0.55 [0.26, 1.16]             |                               |
| Ahn 2008                        |                 |     |        |                               |                               |
| Subtotal (95% CI)                |                 |     |        | 0.55 [0.26, 1.16]             |                               |
| Heterogeneity: Not applicable     |                 |     |        |                               |                               |
| Test for overall effect: Z = 1.57 (P = 0.12) | | | | | |
| 21.5.4 Preterm delivery          | 0.104           | 0.547| 9.6%   | 1.11 [0.38, 3.24]             |                               |
| Ahn 2008                        |                 |     |        |                               |                               |
| Subtotal (95% CI)                |                 |     |        | 1.11 [0.38, 3.24]             |                               |
| Heterogeneity: Not applicable     |                 |     |        |                               |                               |
| Test for overall effect: Z = 0.19 (P = 0.85) | | | | | |
| Total (95% CI)                   |                 |     | 100.0% | 0.82 [0.57, 1.17]             |                               |
| Heterogeneity: Tau² = 0.05; Chi² = 5.90, df = 4 (P = 0.21); I² = 32% | | | | | |
| Test for overall effect: Z = 1.09 (P = 0.28) | | | | | |
| Test for subgroup differences: Chi² = 1.51, df = 3 (P = 0.68), I² = 0% | | | | | |
| (1) Recent use: (within 2 years of pregnancy) | | | | | |
| (2) Prepregnancy use              |                 |     |        |                               |                               |
| (3) Periconception use: 1 month before conception to 1 month postconception | | | | | |
been significant (economic skill building: MD -7.53; 95% CI: -17.24, 2.18; counseling: MD -2.92; 95% CI: -13.17, 7.33) [176]. Interventions teaching coping skills or based on stepwise facilitation seem to significantly lower depression levels and these lowered levels were persistent at the 1-yr follow-up [177]. However, morbidities associated with depressions are higher (Figure 8).

Women with serious mental illnesses are at a greater risk of having had >1 sexual partner or having been raped and are hence more likely to have unplanned, unwanted pregnancies [190]. Their support system has been reported to be generally lacking [191]. They have a greater possibility of engaging in risky behavior during pregnancy (substance abuse, suicide attempts) or of being abused [192]. All this makes it imperative for their physicians to not only screen vigorously for such cases but also to provide comprehensive family planning and contraceptive counseling as well as attach them to relevant support systems.

**Intimate partner violence**

Irrespective of demographics, women around the globe have been subjected to IPV. IPV against women is a major public health concern as it adversely affects both the physical, mental and reproductive health of a woman and that of the newborn. Physical abuse by a partner at some point in life was reported by 13–61% of women of 49 years of age and sexual violence by a partner was reported by 6–59% of them [190]. Violence during pregnancy has been associated with poor health outcomes including increased risk of preterm labor [191], antepartum hemorrhage [192], LBW infants [191], fetal loss [193-195], STIs [196] and post-partum depression [197]. Coker et al. [198] reported that women who ‘ever experienced’ IPV were more than twice as likely to suffer from various kinds of physical and mental health problems. Having experienced IPV is associated with a higher occurrence of unwanted pregnancies [199-201], gynecologic morbidity [202-204] and involvement in risky sexual behaviors [202,204,205]. Data suggests that intensive advocacy interventions may improve the quality of life where as brief advocacy interventions improve safe behaviors [206].

The content of preconception care for women suffering from IPV includes firstly identifying such women, which can be effectively done by asking all women about their experiences of violence from any source, at any point in life. Their condition needs to be evaluated and their injuries treated. Women suffering from IPV need to be informed about the significant harm to the mother, the fetus, and the newborn infant that such abuse can potentially cause and hence of the crucial role of contraceptives. They need be counseled for the psychological trauma that they've suffered from. Finally they need to be referred to an agency/support group that specializes in dealing with such cases. Sexual violence specifically in adolescents is dealt with in the section on ‘Adolescents’ (Reference to paper on adolescent health).
Majority of the reviewed studies on effect of IPV exposure were in women in the general population and were risk aversion studies [191-197,200-205,207-242], while few were intervention studies [176,177,243-253]. From the analysis it was found that IPV positively led to unintended pregnancies (OR 2.33; 95% CI: 1.25-4.34) (Figure 9) [215,218].

No association was found between IPV and condom use in women [196,202,218]. A significant increase in gynecologic morbidities was reported in women suffering from IPV (OR 1.45; 95% CI: 1.13-1.85) [196,203] and rates of STIs were non-significantly raised by around 2 folds in these women (RR 1.89; 95% CI: 0.65-5.47) [202,233]. Gynecologic morbidity increased significantly with any spousal abuse (OR 1.89; 95% CI: 1.23-2.91); combined physical plus sexual violence led to a 72% increase (P 0.04).

With regards to a woman’s physical and mental health, IPV had serious detrimental effects in those abused. Ruiz et al. [254] reported that women who had experienced physical, psychological and sexual violence were twice as likely to suffer a chronic disease as those who have not experienced abuse (OR 2.03; 95% CI: 1.18-3.51), especially diseases other than hypertension, diabetes and asthma (OR 2.57; 95% CI 1.38-4.77) [229], and fetal loss [193]. IPV leads to a towering five-fold increase in depression among the victims (P<0.00001) (Figure 10) [222,224] and a two-fold increase in impairment of mental health in the past month only (RR 2.08; 95% CI: 1.70-2.55) [232,233]. Abuse also makes these women 7 times more likely to contemplate suicide [222].

Interventions targeting IPV have mainly looked at behavioral therapies. These studies have yielded non-significant effects on the occurrence of new events of violence post-treatment. A meta-analysis of 4 trials comparing cognitive behavior therapy (CBT) versus no intervention showed a reduction favoring the intervention group [234]. Behavioral couple’s therapy, when compared to gender specific treatment, showed greater reductions in post-treatment aggression and recidivism rates, especially multiple couple’s group sessions. A dual intervention targeting both IPV and substance abuse showed decreased rates of both in the intervention group (RR 0.71; 95% CI: 0.37-1.38) [188].

Interventions focusing on empowerment of women have been employed to reduce these risks, but their role in decreasing the rate of IPV have so far not been significant. A pilot on the effectiveness of an intervention to reduce male partner reproductive coercion was associated with a large reduction in pregnancy coercion among women who had recently experienced IPV (OR: 0.29; 95% CI: 0.09-0.91) [255].

**Discussion**

Preconception care (diet and exercise counseling, and a stringent glycemic control) for women with preexisting diabetes is effective in addressing the ever-increasing rates of adverse fetal consequences (congenital malformation, perinatal mortality) as well as serious maternal outcomes (preterm labor, level of maternal HbA1c in the first trimester of pregnancy). This review identified significant impact of preconception diabetic care on reducing congenital malformation and perinatal mortality. This finding is in line with the results of some previous reviews [25,256] with the differences being attributed to inclusion of studies with a low to moderate level of bias. The problem however lies in the fact that a substantial number of women with diabetes do not access such preconception care interventions and continue to have unplanned pregnancies with deleterious MNCH results.
Since less than 30% of those with diabetes present for preconception care, every office visit of every female diabetic adolescent or woman of childbearing age should be regarded as a preconception care visit. Also with more women having children in their later years, screening for type 2 diabetes among women of childbearing age becomes more important. Future research, however, needs to aim at evaluating the effectiveness of preconception care on the incidence of other MNCH outcomes like caesarean sections, spontaneous abortions, via proper trials. What it needs more is to find ways of successfully integrating preconception care into the routine care of all women of reproductive age suffering from diabetes.

On the other hand, preconception management is the cornerstone for epilepsy care in women with epilepsy. What is recommended is a multidisciplinary approach, involving the patient’s primary care physician, an obstetrician who specializes in high-risk pregnancies, and a neurologist. Women with epilepsy should be reviewed before planning a pregnancy in order to optimize therapy before conception. Ideally changes in antiepileptic drug therapy should be made at least 6 months before planned conception, if possible. All women with epilepsy should be persuaded to begin folic acid supplementation during reproductive years and continue throughout pregnancy. A recent survey [257] reported that women with epilepsy are not getting the advice they need on issues relating to contraception and pregnancy. This point was also conformed in another study [258] which showed that physicians managing women with epilepsy did not place adequate emphasis on preconception care. The current evidence for preconception counseling is encouraging but not conclusive and requires further thorough investigation. Effective elements of counseling or mode of delivery need to be identified via future research. Trials should be conducted to evaluate the value of counseling or other behavioral interventions in the preconception period in reducing clinically relevant outcomes. While there is an extensive support for the pre-conception counseling of all women of child-bearing years suffering from epilepsy, there is a dearth of evidence evaluating the efficiency of such an intervention in dealing with adverse pregnancy outcomes of the disease and its treatment.

Given the complications of the maternal PKU syndrome, a systematic approach to those intending to get pregnant is required. The analysis revealed a significant positive effect of strict dietary control in the preconception period and improved growth parameters in the newborn. Studies have also reported a decrement in other fetal risks associated with the disease after attainment of an adequate control of phenylalanine levels in the 1st trimester, brought about by following a stringent dietary plan before pregnancy. There is evidence that a preconception phenylalanine-restricted diet works, however what is needed now is to finalize a preconception protocol for women with PKU and implement it on a larger scale for better coverage. An absolute dearth of evidence was also identified in women with thyroid dysfunction. However, logic dictates that ensuring maternal biochemical euthyroidism in the first trimester, when the fetus is most responsive to maternal thyroxine, might optimize fetal outcome. To achieve this target those already suffering from thyroid dysfunction...
need to be re-evaluated before they plan to conceive, their treatment regimens need to be re-adjusted and they need to be counseled about the probable risks to both lives that an unachieved euthyroid status may lead to. Future research not only needs to find the missing link between thyroid function before conception and a fall in associated MNCH morbidities, it also needs to focus on how to achieve this in women with thyroid disorders who want to conceive.

Pregnancy is safe in most lupus patients who conceive while the disease is inactive; however pregnancy statistically increases SLE activity. Active SLE prior to pregnancy is associated with a less favourable maternal and fetal outcome and conception should hence be avoided, if possible. The analysis showed that an active disease status in the preconception period significantly increased the risks of gestational flares by 77%, PIH by over three folds, preterm deliveries by twice as much and perinatal mortality by over two-folds. No association was found with pre-eclampsia, fetal growth restriction or spontaneous abortions. These findings highlight the importance of a preconception intervention to address the reproductive issues in women suffering from SLE. Similarly, several drugs used by women with lupus have been contraindicated during pregnancy for their adverse effects on maternal and fetal outcomes.

This review of the literature found important evidence pertaining to the periconception use of certain drugs used regularly for chronic disorders or other purposes. Antihistamines, especially bronchodilator use, in the periconception period led to a more than two-fold increase in the incidence of gastroschisis. Weight-loss drugs led to a 58% increase in the risk of congenital malformations, especially congenital heart defects. OCPs led to a non-significant increase in various pregnancy and fetal outcomes. Vasocoactive substances, like aspirin, decongestants and vasoconstrictors were associated with limb defects. It is therefore, advisable to women to take these drugs only when prescribed by doctors after thorough assessment of history and examination of potential side effects.

Mental health conditions are prevalent among women of reproductive age and a substantial proportion goes untreated. Due attention is being paid to screening for and treating psychosocial issues during pregnancy and post-partum but non-pregnant women are being neglected in this regard. There is a deficiency of evidence associating the status of disease and treatment in the preconception period with adverse MNCH effects. This explains the lack of literature on effective interventions targeting such women, implementation of which would be a task of its own. Interventions already proved efficacious in pregnancy should also be evaluated for women before pregnancy. IPV, on the other hand, is a serious, widely prevalent issue. Apart from being violations of human rights, acts of violence profoundly damage the physical, sexual, reproductive, emotional, mental and social well-being of not only individuals but families. IPV has adverse effects on women, leading to an increase in unplanned pregnancies, gynecologic infections and probable fetal loss. Current interventions for reducing IPV and related morbidities have mainly looked at behavioral therapies. Behavioral couple’s therapy has shown greater reductions in post-treatment aggression and recidivism rates, especially multiple couple’s group sessions. Although these interventions may not have shown significant effects yet, there is every reason to believe that thorough outcome evaluations of present programmes along with development of new programs based on sound supposition and identified risk factors will translate into a swift expansion in the near future.

Although the review identified the impact of majority of chronic and mental diseases on MNCH outcomes, it was, however, unable to gather evidence on preconception respiratory diseases such as cystic fibrosis, endocrine problems such as ovarian syndrome and women with cancers. This was mainly because of dearth of literature on these topics particularly from preconception period.

Conclusion
Provision of care to high risk women for chronic medical conditions is as important as any other general health promotion. Delaying and achieving optimal timing of a pregnancy is often an important component of the preconception care of women with medical conditions. Since majority of the pregnancies are unplanned, therefore, reproductive planning and contraceptive considerations for women of reproductive age with chronic medical conditions should be discussed early after diagnosis. IPV is a serious, widely prevalent issue. Apart from being violations of human rights, acts of violence profoundly damage the physical, sexual, reproductive, emotional, mental and social well-being of not only individuals but families. IPV has untoward effects on women, leading to an increase in unplanned pregnancies, gynecologic infections and probable fetal loss. Abuse also leads to grave impairment of the physical and mental health of the victims.

Peer review
review reports are included in additional file 1.

Additional material

Additional file 1: Peer review reports.
Competition interests
We do not have any financial or non-financial competing interests for this review.

Acknowledgment
The publication of these papers and supplement was supported by an unrestricted grant from The Partnership for Maternal, Newborn and Child Health.

Declarations
This article has been published as part of Reproductive Health Volume 11 Supplement 2, 2014: Preconception interventions. The full contents of the supplement are available online at http://www.reproductive-health-journal.com/supplements/11/S3. Publication charges for this collection were funded by the Partnership for Maternal, Newborn & Child Health (PMNCH).

Published: 26 September 2014

References
1. Hunt KJ, Schuller KL. The increasing prevalence of diabetes in pregnancy. Obstet Gynecol Clin North Am 2007, 34(2):173-199.
2. Kitzmiller JL, Buchanan TA, Kjos S, Combis CA, Ratner RE. Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Diabetes Care 1996, 19(5):514-541.
3. Ray K, Wernimuller MJ, Meier C, Wyatt PR. Risk of congenital anomalies detected during antenatal serum screening in women with pregestational diabetes. QJM 2004, 97(10):651.
4. Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ, Cunningham FG. Subclinical hypothyroidism and pregnancy outcomes. Obstetrics & Gynecology 2005, 105(2):239.
5. Koch R, Friedman E, Azen C, Hanley W, Levy H, Nataf M, Rouse B, Trefz F, Waisbrein S, Michals-Matalon K. The international collaborative study of maternal phenylketonuria: status report 1998. European journal of pediatrics 2000, 159(14):156-160.
6. Cohen JA. Treating traumatized children: Current status and future directions. Journal of trauma & dissociation 2005, 6(2):109-121.
7. Burt SA, McGue M, Krueger RF, Iacono WG. How are parent-child conflict and childhood externalizing symptoms related over time? Results from a genetically informative cross-lagged study. Development and Psychopathology 2005, 17(01):145-165.
8. Halbreich U. The association between pregnancy processes, preterm delivery, low birth weight, and postpartum depressions—the need for interdisciplinary integration. American journal of obstetrics and gynecology 2005, 193(4):1312-1322.
9. Dean S, Rudan I, Althabe F, Girard AW, Howson C, Langer A, Lawn J, Reever M-E, Teela KC, Toledano M. Setting research priorities for preconception care in low-and-middle income countries: aiming to reduce maternal and child mortality and morbidity. PLoS Med 2013, 10(9):e1001508.
10. WHO WHO. Meeting to develop a global consensus on preconception care to reduce maternal and childhood morbidity and mortality. Geneva: World Health Organization Headquarters; 2012.
11. Dean SV, Lassi ZS, Imam AM, Bhutta ZA. Preconception Care: closing the gap in the continuum of care to achieve improvements in maternal, newborn and child health. Reproductive Health 2014.
12. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.0 [updated February 2008]. In The Cochrane Collaboration Higgins JPT, Green S 2008. Available from http://www.cochranehandbook.org.
13. Brand RA: Editorial: standards of reporting: the CONSORT, QUORAM, and STROBE guidelines. Clin Orthop Relat Res 2009, 467(8):1393-1394.
14. Review Manager (RevMan). [computer program]. Version S.O. Copenhagen: Nordic Cochrane Collaboration; 2008.
15. Passa P. Diabetes trends in Europe. Diabetes/Metabolism Research and Reviews 2002, 18(53):53-58.
16. Fleming DM, Cross KW,aley MA. Recent changes in the prevalence of diabetes presenting for health care. The British Journal of General Practice 2005, 55(517):589.
17. World Health O. Diabetes Action Now: An Initiative of the World Health Organization and the International Diabetes Federation. World Health Organization, 2004.
18. Al-Nuaim AR. Prevalence of glucose intolerance in urban and rural communities in Saudi Arabia. Diabetic Medicine 1997, 14(7):595-602.
19. Bell R, Bailey K, Cresswell T, Hawthorne G, Critchley J, Lewis Barsed N. Trends in prevalence and outcomes of pregnancy in women with preexisting type I and type II diabetes. BIOC: An International Journal of Obstetrics & Gynaecology 2008, 115(4):445-452.
20. Cheung NW, McDuff A, Ross GP. Type 2 diabetes in pregnancy: a wolf in sheep's clothing. Australian and New Zealand Journal of Obstetrics and Gynaecology 2005, 45(6):479-483.
21. Feig DS, Palda VA. Type 2 diabetes in pregnancy: a growing concern. Lancet 2002, 359(9218):1660-1692.
22. Mathiesen ER, Ringholm L, Damm P. Stillbirth in diabetic pregnancies. Best Practice & Research Clinical Obstetrics & Gynaecology 2011, 25(1):105-111.
23. Ganesh KS, Unnikrishnan B, Nagara J, Jayaram S. Determinants of Pre-eclampsia: A Case–control Study in a District Hospital in South India. Indian Journal of Community Medicine: Official Publication of Indian Association of Preventive & Social Medicine 2010, 35(4):502.
24. Shamsi U, Hatcher J, Shami A, Zuberi N, Qadir Z, Saleem S. A multicentre matched case control study to reduce risk factors for Preeclampsia in healthy women in Pakistan. BMJ Women’s Health 2010, 10(1):14.
25. Ray JG, O’Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta analysis. QJM 2003, 96(8):435.
26. Walkinshaw SA. Pregnancy in women with pre-existing diabetes: management issues. 2005, 307.
27. Jensen DM, Damm P, Moeslsted-Pedersen L, Ovlesen P, Westergaard JG, Moeller M, Beck-Nielsen H. Outcomes in type 1 diabetic pregnancies. Diabetes Care 2004, 27(12):2819.
28. Ehnisnberg HM, Mercer BM, Catalano PM. The influence of obesity and diabetes on the prevalence of macrosomia. American journal of obstetrics and gynecology 2004, 191(3):964.
29. Gómez HL, Martínez ML, Rodríguez ZM. Clinical and Epidemiological Profile of Diabetes Mellitus in Pregnancy, Island of Youth, 2008. MEDICC review 2011, 13(1):29.
30. Weintraub N, Karp M, Hod M. Short-and long-range complications in offspring of diabetic mothers. Journal of Diabetes and its Complications 1996, 105(3):294-301.
31. Vitoratos N, Vrachnis N, Valasamakis G, Panoulis K, Creatas G. Perinatal mortality in diabetic pregnancy. Annals of the New York Academy of Sciences 2010, 1205(1):94-99.
32. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996, 174(4):1343-1353.
33. Boulou P, Chabbert-Buffet N, d’Ecole C, Flioriot M, Fontaine P, Fournier A, Gillet JY, Gin H, Grandperret-Vauthier S, Greud AM. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care 2005, 28(11):2980.
34. Damm P, Meldsted-Pedersen L. Significant decrease in congenital malformations in newborn infants of an unselected population of diabetic women. Am J Obstet Gynecol 1989, 161(5):1163-1167.
35. Dicker D, Feldberg D, Samuel N, Yeshaya A, Karp M, Goldman JA. Spontaneous abortion in patients with insulin-dependent diabetes mellitus: the effect of preconceptional diabetic control. Am J Obstet Gynecol 1988, 158(5):1161-1164.
36. Fuhrmann K, Reiher H, Semmler K, Fischer F, Fischer M, Gockler E. Prevention of congenital malformations in infants of insulin-dependent diabetic mothers. Diabetes Care 1983, 6(3):219-223.
37. FüHRMAN K, REIHER H, SEMMLER K, E G. The Effect of Intensified Conventional Insulin Therapy before and during Pregnancy on the Malformation Rate in Offspring of Diabetic.Mothers. Clin Endocrinol 1984, 93(4):213.
38. Galindo A, Garcia Burgallo A, Aziel S, De La Fuente P, Antal R. Outcome of fetuses in women with pregestational diabetes mellitus. Journal of perinatal medicine 2006, 34(4):323-332.
39. Garcia-Fattoross A, Corcoy R, Rigla M, Caballero A, Adelantado JM, Altirriba O, de Leiva A. Does preconceptional counselling in diabetic women influence perinatal outcome? Ann Ist Super Sanita 1997, 33(3):333-336.
40. Goldman JA, Dicker D, Feldberg D, Yeshaya A, Samuel N, Karp M. Pregnancy outcome in patients with insulin-dependent diabetes mellitus with preconceptional diabetic control: a comparative study. Am J Obstet Gynecol 1986, 155(2):295-297.
41. Jaffiol C, Baccara MT, Renaud E, Apostol DJ, Lefebvre P, Boulot P, Daures JP, Bringer J. [Evaluation of the benefits brought by pregnancy planning in type 1 diabetes mellitus]. Bull Acad Natl Med 2000, 184(5):995-1007, discussion 1007-1008.

42. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD: Preconception care of diabetes. JAMA: The Journal of the American Medical Association 1991, 265(6):731.

43. McElvy SS, Miodovnik M, Rosenn B, Khoury JC, Siddiqi T, Dignan PSJ, Tsang RC: A focused preconceptional and early pregnancy program in women with type 1 diabetes reduces perinatal mortality and malformation rates to general population levels. Journal of Maternal-Fetal and Neonatal Medicine 2000, 9(1):14-20.

44. Mills JL, Knopp RH, Simpson JL, Jovanovic-Peterson L, Metzger BE, Holmes LB, Arons JH, Brown Z, Reed GF, Bieker FR, et al: Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. N Engl J Med 1988, 318(11):761-767.

45. Rosenn B, Miodovnik M, Combs BA, Khoury JC, Siddiqi T, Dignan PS: Can preconception care of diabetic women reduce the risk of abnormal babies? British Medical Journal 1990, 301(6760):1070.

46. Temple RC, Aldridge V, Stanley K, Murphy HR: Preconception care and pregnancy outcomes in women with type 1 diabetes. Diabetes Care 2006, 29(8):1744.

47. Willhoite MB, Bennett HW, Palomaki GE, Jr, Zarembs MM, Herman WH, Williams JR, Spear NH: The impact of preconception counseling on pregnancy outcomes. The experience of the Maine Diabetes in Pregnancy Program. Diabetes Care 1993, 16(2):450-455.

48. Dunne FP, Brydon P, Smith T, Essex M, Nicholson H, Dunn J: Preconception care of diabetic women is in insulin-dependent diabetes mellitus. Qm 1999, 92(5):117.

49. Garcia Ingelmo MT, Herranz de la Morena L, Martin Vaquero P, Janez Furio M, Grande Aragon C, Pallardo Sanchez LF: [Preconception control in diabetic women]. Rev Clin Esp 1998, 198(2):80-84.

50. Jensen BM, Kuhl C, Molsted-Pedersen L, Saarbrey N, Fug-Pedersen J: Preconceptional treatment with insulin infusion pumps in insulin-dependent diabetic women with particular reference to prevention of pregnancy malformations. Acta Endocrinol Suppl (Copenhagen) 1988, 277:81-85.

51. Murphy LE, Gollenberg AL, Louis GMB, Kostyniak PJ, Sundaram R: Maternal serum preconception polychlorinated biphenyl concentrations and infant birth weight. Environmental Health Perspectives 2010, 118(2):297.

52. Heller S, Damm P, Mersebach H, Skjøth TV, Kaaja R, Hod M, Durán-García S, McCance D, Mathiesen ER: Hypoglycemia in Type 1 Diabetic Pregnancy. Diabetes Care 2010, 33(3):473.

53. Tripathi A, Rankin J, Harvold J, Chandler C, Bell R: Preconception Counseling in Women With Diabetes. Diabetes Care 2010, 33(3):586.

54. Temple RC, Aldridge V, Stanley K, Murphy HR: Glyceremic control throughout pregnancy and risk of pre-eclampsia in women with type 1 diabetes. BJDOS 2006, 113(11):1329-1332.

55. Morell MJ: Guidelines for the care of women with epilepsy. Neurology 1998, 51(Supplement 4):S21.

56. Stokes T, Shav EI, Juarez-Garcia A, Camasso-Stefanovic J, Baker R: Clinical guidelines and evidence review for the epilepsies: diagnosis and management in adults and children in primary and secondary care. London: Royal College of General Practitioners 2004.

57. Barrett C, Richens A: Epilepsy and pregnancy: Report of an Epilepsy Research Foundation Workshop. Epilepsy research 2003, 52(3):147.

58. Adan N, Kini U, Venten J, Ayres J, Baker G, Clayton-Smith J, Coyle H, Fryer A, Gorry J, Gregg J: The longer term outcome of children born to mothers with epilepsy. Journal of Neurology, Neurosurgery & Psychiatry 2004, 75(11):1575.

59. Adan N, Tudor Smith C, Venten J, Williamson PR: Winterbottom JJ: Common antiepileptic drugs in pregnancy in women with epilepsy. 2004, 1, status and date: Edited (no change to conclusions).

60. Tomson T, Perucca E, Battino D: Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004, 45(10):1711-1715.

61. Ball MJ, Goffaux D, Prichard T, Holmes LB, Aarons JH, Brown Z, Reed GF, Bieber FR, et al: Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. N Engl J Med 1988, 318(11):761-767.

62. Temple RC, Aldridge VJ, Stanley K, Murphy HR: Preconception care of diabetes. JAMA: The Journal of the American Medical Association 1991, 265(6):731.

63. McElvy SS, Miodovnik M, Rosenn B, Khoury JC, Siddiqi T, Dignan PSJ, Tsang RC: A focused preconceptional and early pregnancy program in women with type 1 diabetes reduces perinatal mortality and malformation rates to general population levels. Journal of Maternal-Fetal and Neonatal Medicine 2000, 9(1):14-20.

64. Mills JL, Knopp RH, Simpson JL, Jovanovic-Peterson L, Metzger BE, Holmes LB, Arons JH, Brown Z, Reed GF, Bieker FR, et al: Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. N Engl J Med 1988, 318(11):761-767.

65. Rosenn B, Miodovnik M, Combs BA, Khoury JC, Siddiqi T, Dignan PS: Can preconception care of diabetic women reduce the risk of abnormal babies? British Medical Journal 1990, 301(6760):1070.

66. Temple RC, Aldridge V, Murphy HR: Preconception care and pregnancy outcomes in women with type 1 diabetes. Diabetes Care 2006, 29(8):1744.

67. Willhoite MB, Bennett HW, Palomaki GE, Jr, Zarembs MM, Herman WH, Williams JR, Spear NH: The impact of preconception counseling on pregnancy outcomes. The experience of the Maine Diabetes in Pregnancy Program. Diabetes Care 1993, 16(2):450-455.

68. Dunne FP, Brydon P, Smith T, Essex M, Nicholson H, Dunn J: Preconception care of diabetic women is in insulin-dependent diabetes mellitus. Qm 1999, 92(5):117.

69. Garcia Ingelmo MT, Herranz de la Morena L, Martin Vaquero P, Janez Furio M, Grande Aragon C, Pallardo Sanchez LF: [Preconception control in diabetic women]. Rev Clin Esp 1998, 198(2):80-84.

70. Jensen BM, Kuhl C, Molsted-Pedersen L, Saarbrey N, Fug-Pedersen J: Preconceptional treatment with insulin infusion pumps in insulin-dependent diabetic women with particular reference to prevention of pregnancy malformations. Acta Endocrinol Suppl (Copenhagen) 1988, 277:81-85.

71. Murphy LE, Gollenberg AL, Louis GMB, Kostyniak PJ, Sundaram R: Maternal serum preconception polychlorinated biphenyl concentrations and infant birth weight. Environmental Health Perspectives 2010, 118(2):297.

72. Heller S, Damm P, Mersebach H, Skjøth TV, Kaaja R, Hod M, Durán-García S, McCance D, Mathiesen ER: Hypoglycemia in Type 1 Diabetic Pregnancy. Diabetes Care 2010, 33(3):473.

73. Tripathi A, Rankin J, Harvold J, Chandler C, Bell R: Preconception Counseling in Women With Diabetes. Diabetes Care 2010, 33(3):586.

74. Temple RC, Aldridge V, Stanley K, Murphy HR: Glyceremic control throughout pregnancy and risk of pre-eclampsia in women with type 1 diabetes. BJDOS 2006, 113(11):1329-1332.

75. Morell MJ: Guidelines for the care of women with epilepsy. Neurology 1998, 51(Supplement 4):S21.

76. Stokes T, Shav EI, Juarez-Garcia A, Camasso-Stefanovic J, Baker R: Clinical guidelines and evidence review for the epilepsies: diagnosis and management in adults and children in primary and secondary care. London: Royal College of General Practitioners 2004.

77. Barrett C, Richens A: Epilepsy and pregnancy: Report of an Epilepsy Research Foundation Workshop. Epilepsy research 2003, 52(3):147.

78. Adan N, Kini U, Venten J, Ayres J, Baker G, Clayton-Smith J, Coyle H, Fryer A, Gorry J, Gregg J: The longer term outcome of children born to mothers with epilepsy. Journal of Neurology, Neurosurgery & Psychiatry 2004, 75(11):1575.

79. Adan N, Tudor Smith C, Venten J, Williamson PR: Winterbottom JJ: Common antiepileptic drugs in pregnancy in women with epilepsy. 2004, 1, status and date: Edited (no change to conclusions).

80. Tomson T, Perucca E, Battino D: Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004, 45(10):1711-1715.
176. Hirani SS, Karmali R, McFarlane J, Asad N, Madhani F: Testing a community derived intervention to promote women's health: preliminary results of a 3-arm randomized controlled trial in Karachi, Pakistan. 2010.

177. Buchtan R, McGillicuddy NB: Coping skills training and 12-step facilitation for women whose partner has alcoholism: effects on depression, the partner’s drinking, and partner physical violence. Journal of Consulting and Clinical Psychology 2005, 73(2):249.

178. Miller LJ, Finnerty M: Sexuality, pregnancy, and childbearing among women with schizophrenia-spectrum disorders. Families and Mental Health Treatment: A Compendium of Articles from Psychiatric Services and Hospital and Community Psychiatry 1996, 45.

179. Rudolph B, Larson GL, Sweeny S, Hough EE, Arorien K: Hospitalized pregnant psychotic women: characteristics and treatment issues. Psychiatric Services 1990, 41(2):159.

180. Miller LJ: Psychotic denial of pregnancy: phenomenology and clinical management. Psychiatric Services 1990, 41(1):1233.

181. Seth P, Raji PT, DiClemente RJ, Wingood GM, Rose P: Psychological distress as a correlate of a biologically confirmed STI, risky sexual practices, self-efficacy and communication with male sex partners in African-American female adolescents. Psychology health & medicine 2009, 14(3):291-300.

182. Vigerska AC, Nonacu R, Cohen LS, Tondo L, Murray A, Baldessarini RJ: Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000, 157(2):179-184.

183. Freeman MP, Smith KW, Freeman SA, McElroy SL, Kmetz GE, Wright R, Keck PE: The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry 2002, 63(4):284-287.

184. Li J, Vestergaard M, Obel C, Christiansen J, Precht DH, Lu M, Olsen J: A nationwide study on the risk of autism after prenatal stress exposure to maternal bereavement. Pediatrics 2009, 123(4):1102-1107.

185. Li J, Vestergaard M, Obel C, Precht DH, Christiansen J, Lu M, Olsen J: Prenatal stress and epilepsy in later life: a nationwide follow-up study in Denmark. Epilepsy Res 2008, 81(1):52-57.

186. Li J, Olsen J, Obel C, Christiansen J, Precht DH, Vestergaard M: Prenatal stress and risk of febrile seizures in children: a nationwide longitudinal study in Denmark. J Autism Dev Disord 2009, 39(7):1047-1052.

187. Li J, Olsen J, Vestergaard M, Obel C: Attention-deficit/hyperactivity disorder in the offspring following prenatal maternal bereavement: a nationwide follow-up study in Denmark. Eur Child Adolesc Psychiatry 2010, 19(10):745-753.

188. Li J, Olsen J, Vestergaard M, Obel C, Baker JL, Sorensen TI: Prenatal stress exposure related to maternal bereavement and risk of childhood overweight. PloS One 2010, 5(7):e11896.

189. Hansen D, Lou HC, Olsen J: Serious life events and congenital malformations: a national study with complete follow-up. Lancet 2000, 356(9233):157-160.

190. WHO: Preventing intimate partner and sexual violence against women: Taking action and generating Evidence. 2010.

191. Coker AL, Sanderson M, Dong B: Partner violence during pregnancy and risk of adverse pregnancy outcomes. Paediatr Perinat Epidemiol 2004, 18(4):260-269.

192. Jansson PA, Holt VL, Sugg NK, Emanuel I, Critchlow CM, Henderson AD: Intimate partner violence and contraception use among women in Sub-Saharan Africa. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2009, 107(1):31.

193. Glander SS, Moore ML, Michielse F, Parsons LH: The prevalence of domestic violence among women seeking abortion. Obstet Gynecol 1998, 91(6):1002-1006.

194. Heidn LW, Jansson PO: Domestic violence during pregnancy. The prevalence of physical injuries, substance use, abortions and miscarriages. Acta Obstet Gynecol Scand 2000, 79(8):625-630.

195. Salam MA, Alim MA, Noguchi T: Spousal abuse against women and its consequences on reproductive health: a study in the urban slums in Bangladesh. Maternal and Child Health Journal 2006, 10(1):83-94.

196. Beydoun HA, Al-Sabah B, Beydoun MA, Tamm H: Intimate Partner Violence as a Risk Factor for Postpartum Depression Among Canadian Women in the Maternity Experience Survey. Annals of epidemiology 2010, 20(8):575-583.

197. Coker AL, Weston R, Creason DL, Justice B, Blakeney P: PTSD symptoms among men and women survivors of intimate partner violence: The role of risk and protective factors. Violence and victim 2005, 20(6):625-643.

198. Goodwin MM, Gazmararian JA, Johnson CH, Gilbert BC, Saltzman LE: Pregnancy intendedness and physical abuse around the time of pregnancy: findings from the pregnancy risk assessment monitoring system, 1996-1997. PRAMS Working Group. Pregnancy Risk Assessment Monitoring System. Matern Child Health J 2000, 4(2):65-69.

199. Pallitto CC, O’Campo P: The Relationship between Intimate Partner Violence and Unintended Pregnancy: Analysis of a National Sample from Colombia. International Family Planning Perspectives 2004, 30(4):165-174.

200. Clark CJ, Silverman J, Khalaf IA, Ra’ad BA, Al Sha’ar ZA, Al Ata AA, Batieha A: Intimate partner violence and interference with women’s efforts to avoid pregnancy in Jordan. Studies in Family Planning 2008, 39(2):123-132.

201. Bauer HM, Gibson P, Hernandez M, Kent C, Klauser J, Bolan G: Intimate partner violence and high-risk sexual behaviors among female patients with sexually transmitted diseases. Sexually transmitted diseases 2002, 29(7):411.

202. Stephenson R, Koenig MA, Ahmed S: Domestic violence and symptoms of gynecologic morbidity among women in North India. International Family Planning Perspectives 2006, 32(4):201-208.

203. Seth P, Raiford JL, Robinson LSS, Wingood GM, DiClemente RJ: Intimate partner violence and other partner-related factors: correlates of sexually transmitted infections and risky sexual behaviours among young adult African American women. Sexual Health 2010, 7(1):25-30.

204. Bonomi AE, Thompson RS, Anderson M, Reid RJ, Carrell D, Dimer JA, Rivara FP: Intimate partner violence and women’s physical, mental, and social functioning. Am J Prev Med 2006, 30(6):458-466.

205. Ramsey J, Carter Y, Davidson L, Dunne D, Eldridge S, Hegarty K, Rivas C, Taft A, Warburton A, Feder G: Advocacy interventions to reduce or eliminate violence and promote the physical and psychosocial well-being of women who experience intimate partner abuse. 2009, 4: status and date: Edited (no change in conclusions).

206. McFarlane J, Parker B, Soeken K: Abuse during pregnancy: frequency, severity, perpetrator, and risk factors of homicide. Public Health Nurs 1995, 12(5):284-289.

207. Rodríguez M, Valentine JM, Son JB, Muhammad M: Intimate partner violence and barriers to mental health care for ethnically diverse populations of women. Trauma, Violence & Abuse 2009, 10(4):358.

208. Forte T, Cohen MM, Du Mont J, Hymon I, Romans S: Psychological and physical sequelae of intimate partner violence among women with limitations in their activities of daily living. Archives of women's mental health 2005, 8(4):248-256.

209. Jewkes RK, Dunkle K, Nduna M, Shai N: Intimate partner violence, relationship power inequality, and incidence of HIV infection in young women in South Africa: a cohort study. The Lancet 2010, 376(9734):41-48.

210. Macy RJ, Martin SL, Kupper LL, Casanueva C, Guo S: Intimate partner violence and high-risk sexual behaviors among female patients with sexually transmitted diseases. Sexually transmitted diseases 2002, 29(7):411.

211. Stephenson R, Koenig MA, Ahmed S: Domestic violence and symptoms of gynecologic morbidity among women in North India. International Family Planning Perspectives 2006, 32(4):201-208.
behaviour, and STI/HIV diagnosis among a clinic-based sample of men. Sexually transmitted infections 2009, 85(7):555.
218. Gómez AM, Speizer S, Beausais H: Sexual violence and reproductive health among youths in Port-au-Prince, Haiti. Journal of Adolescent Health 2009, 44(5):508-510.
219. Smedslund G, Dalbasa TK, Steiro AK, Winsvold A, Clench-Aas J. Cognitive behavioural therapy for men who physically abuse their female partner (Review). 2011.
220. Decker MR, Miller E, Kapur NA, Gupta J, Raj A, Silverman JG: Intimate partner violence and sexually transmitted disease symptoms in a national sample of married Bangladeshi women. International Journal of Gynecology & Obstetrics 2008, 100(1):18-23.
221. McFarlane J, Malecha A, Watson K, Gist J, Batten E, Hall I, Smith S: Intimate partner sexual assault against women: frequency, health consequences, and treatment outcomes. Obstetrics & Gynecology 2005, 105(1):99.
222. Hurwitz EH, Gupta J, Liu R, Silverman JG, Raj A: Intimate partner violence associated with poor health outcomes in US South Asian women. Journal of Immigrant and Minority Health 2006, 8(3):251-261.
223. Stein MR, Kennedy C: Major depressive and post-traumatic stress disorder comorbidity in female victims of intimate partner violence. Journal of Affective Disorders 2001, 66(2-3):131-138.
224. Hegarty K, Gunn J, Chondros P, Small R: Perpetration of partner violence and HIV risk behaviour among young adult men. Archives of family medicine 2000, 29(2):121-126.
225. Martin SL, Rentz ED, Chan RL, Givens J, Sanford CP, Kupper LL, Lassi et al.: European Journal of Public Health 2009, 20(1):1873.
226. Naimi TS, Lipscomb LE, Brewer RD, Gilbert BC: Binge drinking in the preconception period and the risk of unintended pregnancy: implications for women and their children. Pediatrics 2001, 111(3):133-138.
227. Leary KD, Heyman RE, Neidig PH: Treatment of wife abuse: A comparison of gender-specific and conjoint approaches. Behavior Therapy 1999, 30(3):475-505.
228. Markman HJ, Renick MJ, Floyd FJ, Stanley SM, Clemmets M: Preventing marital distress through communication and conflict management training: A 4-and 5-year follow-up. Journal of Consulting and Clinical Psychology 1993, 61(1):70.
229. Davis RC, Taylor BG, Maxwell CD, Victim Services R: Testing the effectiveness of batterer programs and judicial monitoring. Final report (National Institute of Justice, Washington, DC) 2005.
230. Davis RC, Taylor BG, Maxwell CD, Victim Services R: Does Batterer Treatment Reduce Violence? A Randomized Experiment in Brooklyn—Executive Summary Included. 2000.
231. Llabiola M, Rempel M, Davis RC: Does Batterer Treatment Within Intact Couple Relationships: OUTCOMES OF MULTI COUPLE VERSUS INDIVIDUAL COUPLE THERAPY. Journal of Marital and Family Therapy 2004, 30(3):305-318.
232. Martin SL, Rentz ED, Chan RL, Givens J, Sanford CP, Kupper LL, Lassi et al.: Preventing marital distress through communication and conflict management training: A 4-and 5-year follow-up. Journal of Consulting and Clinical Psychology 1993, 61(1):70.
233. Simpson LE, Atkins DC, Gattis KS, Christensen A: Low-level relationship aggression and couple therapy outcomes. Journal of Family Psychology 2008, 22(1):102.
234. Stith SM, Rosen H, McCollum EE, Thomsen CJ: Treating intimate partner violence within intact couple relationships: outcomes of multi couple versus individual couple therapy. Journal of Marital and Family Therapy 2004, 30(3):305-318.
235. Davis RC, Taylor BG, Maxwell CD, Victim Services R: Does Batterer Treatment Reduce Violence? A Randomized Experiment in Brooklyn—Executive Summary Included. 2000.
236. Leary KD, Heyman RE, Neidig PH: Treatment of wife abuse: A comparison of gender-specific and conjoint approaches. Behavior Therapy 1999, 30(3):475-505.
237. Markman HJ, Renick MJ, Floyd FJ, Stanley SM, Clemmets M: Preventing marital distress through communication and conflict management training: A 4-and 5-year follow-up. Journal of Consulting and Clinical Psychology 1993, 61(1):70.
238. Simpson LE, Atkins DC, Gattis KS, Christensen A: Low-level relationship aggression and couple therapy outcomes. Journal of Family Psychology 2008, 22(1):102.
239. Stith SM, Rosen H, McCollum EE, Thomsen CJ: Treating INTIMATE PARTNER VIOLENCE WITHIN INTACT COUPLE RELATIONSHIPS: OUTCOMES OF MULTI COUPLE VERSUS INDIVIDUAL COUPLE THERAPY. Journal of Marital and Family Therapy 2004, 30(3):305-318.
240. Davis RC, Taylor BG, Maxwell CD, Victim Services R: Does Batterer Treatment Reduce Violence? A Randomized Experiment in Brooklyn—Executive Summary Included. 2000.
241. Leary KD, Heyman RE, Neidig PH: Treatment of wife abuse: A comparison of gender-specific and conjoint approaches. Behavior Therapy 1999, 30(3):475-505.
242. Markman HJ, Renick MJ, Floyd FJ, Stanley SM, Clemmets M: Preventing marital distress through communication and conflict management training: A 4-and 5-year follow-up. Journal of Consulting and Clinical Psychology 1993, 61(1):70.
243. Simpson LE, Atkins DC, Gattis KS, Christensen A: Low-level relationship aggression and couple therapy outcomes. Journal of Family Psychology 2008, 22(1):102.
244. Stith SM, Rosen H, McCollum EE, Thomsen CJ: Treating INTIMATE PARTNER VIOLENCE WITHIN INTACT COUPLE RELATIONSHIPS: OUTCOMES OF MULTI COUPLE VERSUS INDIVIDUAL COUPLE THERAPY. Journal of Marital and Family Therapy 2004, 30(3):305-318.
245. Labriola M, Rempel M, Davis RC: Does batterer programs and judicial monitoring. Final report (National Institute of Justice, Washington, DC) 2005.
246. Davis RC, Taylor BG, Maxwell CD, Victim Services R: Does Batterer Treatment Reduce Violence? A Randomized Experiment in Brooklyn—Executive Summary Included. 2000.
247. Leary KD, Heyman RE, Neidig PH: Treatment of wife abuse: A comparison of gender-specific and conjoint approaches. Behavior Therapy 1999, 30(3):475-505.